| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 35,731 | -11,227 | -30,260 |
| Depreciation and amortization | -674 | 227 | 494 |
| Stock-based compensation | -6,683 | 2,136 | 5,200 |
| Amortization of premiums and discounts on marketable securities | -1,769 | 494 | 1,275 |
| Amortization of debt discount and issuance costs and other non-cash interest | -238 | 37 | 201 |
| Impairment loss of right-of-use asset | NaN | 0 | 0 |
| Loss on fixed asset write-off | 119 | NaN | NaN |
| Reclassification of currency translation loss | NaN | 282 | NaN |
| Gain on sale of nonfinancial asset | 1,000 | NaN | NaN |
| Gain on disposition of fixed assets | 5 | 4 | NaN |
| Prepaid expenses and other current assets | -1,042 | 432 | -1,390 |
| Other assets | 2,415 | -674 | -1,741 |
| Accounts payable, accrued and other current liabilities | 3,908 | -426 | -6,322 |
| Operating lease assets and liabilities | -1,098 | 603 | 1,154 |
| Net cash used in operating activities | 32,370 | -9,830 | -29,985 |
| Purchases of property and equipment | -8 | 0 | 8 |
| Proceeds from sale of nonfinancial asset | 1,000 | NaN | NaN |
| Proceeds from sale of fixed assets | 520 | 9 | NaN |
| Purchases of marketable securities | NaN | 14,297 | 28,334 |
| Maturities of marketable securities | -83,481 | 30,000 | 53,481 |
| Net cash provided by investing activities | -39,322 | 15,712 | 25,139 |
| Repayment of loan principal | -3,913 | 1,305 | 2,608 |
| Proceeds from issuance of common stock under employee stock incentive plans | 232 | 0 | 35 |
| Net cash provided by (used in) financing activities | 4,145 | -1,305 | -2,573 |
| Effect of exchange rate changes on cash and cash equivalents | -28 | -9 | 37 |
| Net decrease in cash and cash equivalents | -2,835 | 4,568 | -7,382 |
| Cash and cash equivalents at the beginning of period | 38,935 | 41,749 | NaN |
| Cash and cash equivalents at the end of period | 66,229 | 38,935 | NaN |
Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. (KZR)